G Ital Nefrol. 2010 Nov-Dec;27 Suppl 52:S27-31.

[Cardioprotective effect of vitamin D in nondialyzed patients with stage 3-5 CKD].

[Article in Italian]

Cozzolino M, Mehmeti F, Bonelli F, Ronga C, Musetti C, Missaglia E, Stucchi A, Colombo F, Tavecchia M, Cuoccio P, Brenna I, Volpi E, Ciceri P, Cusi D.

Source

U.O. Nefrologia e Dialisi, A.O. San Paolo, Cattedra di Nefrologia, Universita' degli Studi, Milano, Italy. mario.cozzolino@hotmail.hotmail.com

Abstract

Epidemiological and observational data indicate that there is a close relationship between progressive renal dysfunction in chronic kidney disease (CKD), cardiovascular disease, and mortality. In addition, deficits in vitamin D (25-hydroxyvitamin D) and vitamin D receptor (VDR) activation play a crucial role in adversely affecting cardiovascular health in CKD patients. Even in patients with mild CKD, renal dysfunction is associated with cardiovascular events. Modulation of vitamin D levels results in correlative regulatory effects on mineral homeostasis, hypertension, and vascular calcification. The use of VDR activators such as paricalcitol to treat these and other parameters outside of cardiovascular and renal disease not only results in enhanced patient health but significantly reduces the mortality risk in CKD patients.

PMID:: 21132659; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

English Abstract

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

EBSCO

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Supplemental Content

Save items

Related citations in PubMed

[Prevention and treatment of secondary hyperparathyroidism in non-dialyzed patients with stage 3-5 chronic kidney diease]. [G Ital Nefrol. 2009]
[Prevention and treatment of secondary hyperparathyroidism in non-dialyzed patients with stage 3-5 chronic kidney diease].
Cozzolino M, Olivi L, Voli E, Ciceri P, Brancaccio D. G Ital Nefrol. 2009 Nov-Dec; 26 Suppl 49:S30-5.
Review Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? [Kidney Int. 2005]
Review Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease?
Levin A, Li YC. Kidney Int. 2005 Nov; 68(5):1973-81.
Review Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. [J Manag Care Pharm. 2007]
Review Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Joy MS, Karagiannis PC, Peyerl FW. J Manag Care Pharm. 2007 Jun; 13(5):397-411.
Review Use of vitamin D in chronic kidney disease patients. [Kidney Int. 2010]
Review Use of vitamin D in chronic kidney disease patients.
Gal-Moscovici A, Sprague SM. Kidney Int. 2010 Jul; 78(2):146-51. Epub 2010 May 26.
[Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)]. [Nefrologia. 2008]
[Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V, Torregrosa V. Nefrologia. 2008; 28 Suppl 3:67-78.

See reviews... See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.

Recent activity

Clear Turn Off Turn On

[Cardioprotective effect of vitamin D in nondialyzed patients with stage 3-5 CKD...
[Cardioprotective effect of vitamin D in nondialyzed patients with stage 3-5 CKD].
G Ital Nefrol. 2010 Nov-Dec ;27 Suppl 52:S27-31.

PubMed
Archaea--timeline of the third domain.
Archaea--timeline of the third domain.
Nat Rev Microbiol. 2011 Jan ;9(1):51-61. Epub 2010 Dec 6 .

PubMed
GNL3L depletion destabilizes MDM2 and induces p53-dependent G2/M arrest.
GNL3L depletion destabilizes MDM2 and induces p53-dependent G2/M arrest.
Oncogene. 2011 Apr 7 ;30(14):1716-26. Epub 2010 Dec 6 .

PubMed
CEP152 is a genome maintenance protein disrupted in Seckel syndrome.
CEP152 is a genome maintenance protein disrupted in Seckel syndrome.
Nat Genet. 2011 Jan ;43(1):23-6. Epub 2010 Dec 5 .

PubMed
Pulmonary fibrosis inducer, bleomycin, causes redox-sensitive activation of phos...
Pulmonary fibrosis inducer, bleomycin, causes redox-sensitive activation of phospholipase D and cytotoxicity through formation of bioactive lipid signal mediator, phosphatidic acid, in lung microvascular endothelial cells.
Int J Toxicol. 2011 Feb ;30(1):69-90. Epub 2010 Dec 3 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: